Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate

Chest

Volumn 121, Issue 6, 2002, Pages 1824-1832

  Juniper, Elizabeth F ^a   Price, David B ^b   Stampone, Patti A ^c   Creemers, Jacques P H M ^d   Mol, Stijn J M ^e   Fireman, Philip ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c 3M COMPANY   (United States)

^d CATHARINA HOSPITAL   (Netherlands)

^e ST JOSEPH HOSPITAL   (Netherlands)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Asthma; Beclomethasone dipropionate; Chlorofluorocarbon; Clinical trial; Hydrofluoroalkane 134a; Inhaled corticosteroids; Metered dose inhaler; Quality of life

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; STEROID;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036279645     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.6.1824     Document Type: Article

References (17)

1. The Montreal Protocol on substances that deplete the ozone layer: Final act (Nairobi: UNEP 1987)
2. New delivery systems and propellants
3. European Community: Strategy for the phaseout of CFCs in metered dose inhalers. A communication from the European Commission to the Council and the European Parliament
4. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
5. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
6. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
7. Improved delivery of inhaled steroids to the large and small airways
8. Quality of life in asthma clinical trials: Comparison of salmeterol and salbutamol
9. Health-related quality of life in moderate asthma: 400 μg hydrofluoroalkane beclomethasone dipropionate vs 800 μg chlorofluorocarbon beclomethasone dipropionate; The Study Group
10. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
11. Long-term safety and efficacy of a CFC-free beclomethasone dipropionate extrafine aerosol
12. Quality of life in adults and children with asthma and rhinitis
13. Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials
14. Standardization of spirometry, 1987 update: Statement of the American Thoracic Society
15. Calculating confidence intervals for regression and correlation
16. Interpreting treatment effects in randomised trials
17. Determining a minimal important change in a disease-specific quality of life questionnaire